Skip to main content
Clinical Trials/NCT03672396
NCT03672396
Completed
N/A

Feasibility Study of a Home-Based Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

UNC Lineberger Comprehensive Cancer Center2 sites in 1 country22 target enrollmentApril 1, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Castration-resistant Prostate Cancer
Sponsor
UNC Lineberger Comprehensive Cancer Center
Enrollment
22
Locations
2
Primary Endpoint
Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing.
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This single arm, multi-site pilot study aims to evaluate the feasibility of recruiting and adherence to a 12 week home-based exercise intervention to be conducted in men with metastatic castration resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Thirty patients will be enrolled, with the expectation that 20-25 will complete all follow-up measures.

Detailed Description

The purpose of this trial is to evaluate the feasibility and adherence to a home-based 12 week exercise intervention in mCRPC patients receiving ADT. It will also examine if a home-based exercise intervention can improve muscle strength, body composition, physical function, cardiopulmonary function fatigue, and patient reported outcomes (fatigue, depression, quality of life (QoL)).

Registry
clinicaltrials.gov
Start Date
April 1, 2017
End Date
December 31, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Metastatic disease that has progressed despite castrate levels of testosterone (surgically or medically castrated, with testosterone levels of \< 50 ng/dL) receiving ADT. This will be verified by assessing total testosterone levels within 4 weeks prior to enrollment.
  • No current chemotherapy.
  • Patients may be receiving additional hormonal therapy agents including but not limited to antiandrogens (e.g. bicalutamide, enzalutamide) and CYP17 inhibitors (e.g. abiraterone).
  • Ability to engage safely in moderate exercise as determined by their treating physician.
  • Not previously engaged in regular exercise training (\<3 or more d/wk for \> 30 min/d or \<90 mins per week total including strength training, aerobic training, or walking) in the past 6 months.
  • Access to a computer or a smart phone for syncing and uploading wearable activity data.
  • Be able to speak and read English.

Exclusion Criteria

  • Any condition that causes severe pain with exertion.
  • History of bone fractures.
  • Active cardiovascular disease including any of the following:
  • New York Heart Association (NYHA) Grade II or greater congestive heart failure .
  • History of myocardial infarction or unstable angina within 6 months prior to Day
  • History of stroke or transient ischemic attack within 6 months prior to Day
  • Acute or chronic respiratory disease that is severe enough to compromise the ability of the participant to safely engage in exercise training protocol.
  • Acute or chronic bone/joint/muscular abnormalities compromising their ability to exercise.
  • Neurological conditions that affect balance and, or muscle strength.
  • Dementia, altered mental status or any psychiatric condition prohibiting the understanding or rendering of informed consent.

Outcomes

Primary Outcomes

Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing.

Time Frame: 12 weeks after baseline testing

To estimate the feasibility of a 12 week, home-based exercise intervention in metastatic castrate resistant prostate cancer (mCPRC) patients undergoing androgen deprivation therapy by reporting the percentage of patients who complete the pre/post testing following the intervention. This was calculated as the number of subjects who completed the trial compared to the total number who completed baseline testing.

Secondary Outcomes

  • Patient Reported Outcomes: Depression(12 weeks after baseline testing)
  • Lean Mass(12 weeks after baseline testing)
  • Physical Function: 6m Walk(12 weeks after baseline testing)
  • Muscle Quality(12 weeks after baseline testing)
  • Chest Press Maximal Strength(12 weeks after baseline testing)
  • Chest Press Muscle Endurance(12 weeks after baseline testing)
  • Fat Mass(12 weeks after baseline testing)
  • Physical Function: Timed Up and Go(12 weeks after baseline testing)
  • Patient Reported Outcomes: Quality of Life(12 weeks after baseline testing)
  • Muscle Size (Cross-sectional Area)(12 weeks after baseline testing)
  • Leg Press Muscle Endurance(12 weeks after baseline testing)
  • Adherence to the Intervention(12 weeks after baseline testing)
  • Patient Reported Outcomes: Fatigue(12 weeks after baseline testing)
  • Cardiopulmonary Function(12 weeks after baseline testing)
  • Physical Function: Stair Climb(12 weeks after baseline testing)
  • Physical Function: 400m Walk(12 weeks after baseline testing)
  • Patient Reported Outcomes: Anxiety(12 weeks after baseline testing)
  • Leg Press Maximal Strength(12 weeks after baseline testing)
  • Percent Body Fat(12 weeks after baseline testing)

Study Sites (2)

Loading locations...

Similar Trials